Arrowhead Pharmaceuticals Ownership
| HDP1 Stock | EUR 21.10 0.45 2.18% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Arrowhead |
Arrowhead Stock Ownership Analysis
About 69.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 263.63. Arrowhead Pharmaceuticals recorded a loss per share of 1.29. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 17th of November 2011. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. ARROWHEAD PHARMAC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 116 people. To learn more about Arrowhead Pharmaceuticals call Christopher Anzalone at 626 304 3400 or check out https://arrowheadpharma.com.Arrowhead Pharmaceuticals Outstanding Bonds
Arrowhead Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Arrowhead Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Arrowhead bonds can be classified according to their maturity, which is the date when Arrowhead Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Arrowhead Stock
When determining whether Arrowhead Pharmaceuticals is a strong investment it is important to analyze Arrowhead Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Arrowhead Pharmaceuticals' future performance. For an informed investment choice regarding Arrowhead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Arrowhead Stock please use our How to Invest in Arrowhead Pharmaceuticals guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.